Distribution of Baseline Characteristics Overall and in Relation to CD4 Count (Cells/µL) and HIV Viral Load (Copies/mL)
| Variablea . | Total N = 383 N (%)b . | CD4 Count (Cells/mm3) . | HIV RNA Viral Load (Copies/mL) . | |||
|---|---|---|---|---|---|---|
| <200 N = 89 N (%)b . | ≥200 N = 288 N (%)b . | ≤75 N = 155 N (%)b . | 76–10 000 N = 119 N (%)b . | >10 000 N = 92 N (%)b . | ||
| Age >45 years | 212 (55) | 43 (48) | 166 (58) | 107 (69) | 62 (52) | 34 (37) |
| Male | 276 (72) | 66 (74) | 205 (71) | 118 (76) | 78 (66) | 66 (72) |
| Race | ||||||
| Black non-Hispanic | 171 (45) | 36 (40) | 132 (46) | 76 (49) | 48 (40) | 38 (41) |
| White non-Hispanic | 104 (27) | 24 (27) | 78 (27) | 38 (25) | 38 (32) | 25 (27) |
| Hispanic | 100 (26) | 28 (31) | 71 (25) | 37 (24) | 32 (27) | 26 (28) |
| Other | 8 (2) | 1 (1) | 7 (2) | 4 (3) | 1 (1) | 3 (3) |
| History of diabetes | 41 (11) | 9 (10) | 31 (11) | 24 (15) | 8 (7) | 7 (8) |
| Markers of HBV | 272 (78) | 68 (83) | 200 (76) | 111 (77) | 81 (76) | 71 (80) |
| FIB-4 | ||||||
| <1.45 (mild fibrosis) | 151 (41) | 32 (38) | 115 (41) | 64 (42) | 46 (39) | 36 (40) |
| 1.45–3.25 (moderate) | 147 (40) | 29 (34) | 117 (42) | 61 (40) | 48 (41) | 34 (38) |
| >3.25 (advanced) | 72 (19) | 24 (28) | 48 (17) | 29 (19) | 24 (20) | 19 (21) |
| HCV genotype 1 | 176 (80) | 41 (85) | 133 (79) | 74 (77) | 59 (83) | 39 (80) |
| HCV viral load ≥106 IU/mL | 106 (47) | 31 (58) | 74 (44) | 39 (44) | 36 (51) | 28 (47) |
| HCV treatment | 27 (7) | 4 (5) | 23 (8) | 13 (9) | 9 (8) | 5 (6) |
| Duration of IDU >25 years | 154 (48) | 40 (51) | 113 (47) | 67 (51) | 52 (53) | 30 (38) |
| Current IDU | 103 (27) | 30 (34) | 71 (25) | 30 (20) | 36 (31) | 30 (33) |
| AUDIT | ||||||
| <8 | 102 (56) | 24 (51) | 76 (58) | 40 (63) | 34 (57) | 24 (46) |
| 8–19 (hazardous) | 54 (30) | 14 (30) | 37 (28) | 13 (21) | 18 (30) | 20 (38) |
| ≥20 (dependence) | 27 (15) | 9 (19) | 18 (14) | 10 (16) | 8 (13) | 8 (15) |
| Nadir CD4 | ||||||
| <50 | 61 (16) | 46 (52) | 15 (5) | 22 (14) | 19 (16) | 18 (20) |
| 50–199 | 114 (30) | 42 (48) | 71 (25) | 48 (31) | 31 (26) | 32 (35) |
| ≥200 | 203 (54) | 0 (0) | 202 (70) | 85 (55) | 69 (58) | 41 (45) |
| CD4 | ||||||
| <200 | 89 (24) | 89 (100) | 0 (0) | 19 (12) | 26 (22) | 40 (43) |
| 200–499 | 161 (43) | 0 (0) | 161 (56) | 72 (47) | 54 (45) | 32 (35) |
| ≥500 | 127 (34) | 0 (0) | 127 (44) | 63 (41) | 39 (33) | 20 (22) |
| HIV RNA | ||||||
| ≤75 | 155 (42) | 19 (22) | 135 (48) | 155 (100) | 0 (0) | 0 (0) |
| 76–10 000 | 119 (33) | 26 (31) | 93 (33) | 0 (0) | 119 (100) | 0 (0) |
| >10 000 | 92 (25) | 40 (47) | 52 (19) | 0 (0) | 0 (0) | 92 (100) |
| Initiated ART | ||||||
| At baseline | 281 (81) | 65 (79) | 212 (82) | 130 (88) | 83 (80) | 62 (78) |
| In follow-up | 37 (11) | 12 (15) | 25 (10) | 13 (9) | 10 (10) | 9 (11) |
| Never | 27 (8) | 5 (6) | 21 (8) | 5 (3) | 11 (11) | 9 (11) |
| Variablea . | Total N = 383 N (%)b . | CD4 Count (Cells/mm3) . | HIV RNA Viral Load (Copies/mL) . | |||
|---|---|---|---|---|---|---|
| <200 N = 89 N (%)b . | ≥200 N = 288 N (%)b . | ≤75 N = 155 N (%)b . | 76–10 000 N = 119 N (%)b . | >10 000 N = 92 N (%)b . | ||
| Age >45 years | 212 (55) | 43 (48) | 166 (58) | 107 (69) | 62 (52) | 34 (37) |
| Male | 276 (72) | 66 (74) | 205 (71) | 118 (76) | 78 (66) | 66 (72) |
| Race | ||||||
| Black non-Hispanic | 171 (45) | 36 (40) | 132 (46) | 76 (49) | 48 (40) | 38 (41) |
| White non-Hispanic | 104 (27) | 24 (27) | 78 (27) | 38 (25) | 38 (32) | 25 (27) |
| Hispanic | 100 (26) | 28 (31) | 71 (25) | 37 (24) | 32 (27) | 26 (28) |
| Other | 8 (2) | 1 (1) | 7 (2) | 4 (3) | 1 (1) | 3 (3) |
| History of diabetes | 41 (11) | 9 (10) | 31 (11) | 24 (15) | 8 (7) | 7 (8) |
| Markers of HBV | 272 (78) | 68 (83) | 200 (76) | 111 (77) | 81 (76) | 71 (80) |
| FIB-4 | ||||||
| <1.45 (mild fibrosis) | 151 (41) | 32 (38) | 115 (41) | 64 (42) | 46 (39) | 36 (40) |
| 1.45–3.25 (moderate) | 147 (40) | 29 (34) | 117 (42) | 61 (40) | 48 (41) | 34 (38) |
| >3.25 (advanced) | 72 (19) | 24 (28) | 48 (17) | 29 (19) | 24 (20) | 19 (21) |
| HCV genotype 1 | 176 (80) | 41 (85) | 133 (79) | 74 (77) | 59 (83) | 39 (80) |
| HCV viral load ≥106 IU/mL | 106 (47) | 31 (58) | 74 (44) | 39 (44) | 36 (51) | 28 (47) |
| HCV treatment | 27 (7) | 4 (5) | 23 (8) | 13 (9) | 9 (8) | 5 (6) |
| Duration of IDU >25 years | 154 (48) | 40 (51) | 113 (47) | 67 (51) | 52 (53) | 30 (38) |
| Current IDU | 103 (27) | 30 (34) | 71 (25) | 30 (20) | 36 (31) | 30 (33) |
| AUDIT | ||||||
| <8 | 102 (56) | 24 (51) | 76 (58) | 40 (63) | 34 (57) | 24 (46) |
| 8–19 (hazardous) | 54 (30) | 14 (30) | 37 (28) | 13 (21) | 18 (30) | 20 (38) |
| ≥20 (dependence) | 27 (15) | 9 (19) | 18 (14) | 10 (16) | 8 (13) | 8 (15) |
| Nadir CD4 | ||||||
| <50 | 61 (16) | 46 (52) | 15 (5) | 22 (14) | 19 (16) | 18 (20) |
| 50–199 | 114 (30) | 42 (48) | 71 (25) | 48 (31) | 31 (26) | 32 (35) |
| ≥200 | 203 (54) | 0 (0) | 202 (70) | 85 (55) | 69 (58) | 41 (45) |
| CD4 | ||||||
| <200 | 89 (24) | 89 (100) | 0 (0) | 19 (12) | 26 (22) | 40 (43) |
| 200–499 | 161 (43) | 0 (0) | 161 (56) | 72 (47) | 54 (45) | 32 (35) |
| ≥500 | 127 (34) | 0 (0) | 127 (44) | 63 (41) | 39 (33) | 20 (22) |
| HIV RNA | ||||||
| ≤75 | 155 (42) | 19 (22) | 135 (48) | 155 (100) | 0 (0) | 0 (0) |
| 76–10 000 | 119 (33) | 26 (31) | 93 (33) | 0 (0) | 119 (100) | 0 (0) |
| >10 000 | 92 (25) | 40 (47) | 52 (19) | 0 (0) | 0 (0) | 92 (100) |
| Initiated ART | ||||||
| At baseline | 281 (81) | 65 (79) | 212 (82) | 130 (88) | 83 (80) | 62 (78) |
| In follow-up | 37 (11) | 12 (15) | 25 (10) | 13 (9) | 10 (10) | 9 (11) |
| Never | 27 (8) | 5 (6) | 21 (8) | 5 (3) | 11 (11) | 9 (11) |
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders identification test; FIB-4, fibrosis-4; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug use.
a Missing observations for each variable (N, %): age, 0 (0); sex, 0 (0); race, 0 (0); diabetes, 0 (0); HBV, 33 (9); FIB-4, 13 (3); HCV genotype, 162 (42); HCV viral load, 157 (41); HCV treatment, 19 (5); years of IDU, 60 (16); current IDU, 3 (1); alcohol, 200 (52); nadir CD4, 5 (1); CD4, 6 (2); HIV viral load, 17 (4); ART initiation, 38 (10).
b Percentages are among the nonmissing.
Distribution of Baseline Characteristics Overall and in Relation to CD4 Count (Cells/µL) and HIV Viral Load (Copies/mL)
| Variablea . | Total N = 383 N (%)b . | CD4 Count (Cells/mm3) . | HIV RNA Viral Load (Copies/mL) . | |||
|---|---|---|---|---|---|---|
| <200 N = 89 N (%)b . | ≥200 N = 288 N (%)b . | ≤75 N = 155 N (%)b . | 76–10 000 N = 119 N (%)b . | >10 000 N = 92 N (%)b . | ||
| Age >45 years | 212 (55) | 43 (48) | 166 (58) | 107 (69) | 62 (52) | 34 (37) |
| Male | 276 (72) | 66 (74) | 205 (71) | 118 (76) | 78 (66) | 66 (72) |
| Race | ||||||
| Black non-Hispanic | 171 (45) | 36 (40) | 132 (46) | 76 (49) | 48 (40) | 38 (41) |
| White non-Hispanic | 104 (27) | 24 (27) | 78 (27) | 38 (25) | 38 (32) | 25 (27) |
| Hispanic | 100 (26) | 28 (31) | 71 (25) | 37 (24) | 32 (27) | 26 (28) |
| Other | 8 (2) | 1 (1) | 7 (2) | 4 (3) | 1 (1) | 3 (3) |
| History of diabetes | 41 (11) | 9 (10) | 31 (11) | 24 (15) | 8 (7) | 7 (8) |
| Markers of HBV | 272 (78) | 68 (83) | 200 (76) | 111 (77) | 81 (76) | 71 (80) |
| FIB-4 | ||||||
| <1.45 (mild fibrosis) | 151 (41) | 32 (38) | 115 (41) | 64 (42) | 46 (39) | 36 (40) |
| 1.45–3.25 (moderate) | 147 (40) | 29 (34) | 117 (42) | 61 (40) | 48 (41) | 34 (38) |
| >3.25 (advanced) | 72 (19) | 24 (28) | 48 (17) | 29 (19) | 24 (20) | 19 (21) |
| HCV genotype 1 | 176 (80) | 41 (85) | 133 (79) | 74 (77) | 59 (83) | 39 (80) |
| HCV viral load ≥106 IU/mL | 106 (47) | 31 (58) | 74 (44) | 39 (44) | 36 (51) | 28 (47) |
| HCV treatment | 27 (7) | 4 (5) | 23 (8) | 13 (9) | 9 (8) | 5 (6) |
| Duration of IDU >25 years | 154 (48) | 40 (51) | 113 (47) | 67 (51) | 52 (53) | 30 (38) |
| Current IDU | 103 (27) | 30 (34) | 71 (25) | 30 (20) | 36 (31) | 30 (33) |
| AUDIT | ||||||
| <8 | 102 (56) | 24 (51) | 76 (58) | 40 (63) | 34 (57) | 24 (46) |
| 8–19 (hazardous) | 54 (30) | 14 (30) | 37 (28) | 13 (21) | 18 (30) | 20 (38) |
| ≥20 (dependence) | 27 (15) | 9 (19) | 18 (14) | 10 (16) | 8 (13) | 8 (15) |
| Nadir CD4 | ||||||
| <50 | 61 (16) | 46 (52) | 15 (5) | 22 (14) | 19 (16) | 18 (20) |
| 50–199 | 114 (30) | 42 (48) | 71 (25) | 48 (31) | 31 (26) | 32 (35) |
| ≥200 | 203 (54) | 0 (0) | 202 (70) | 85 (55) | 69 (58) | 41 (45) |
| CD4 | ||||||
| <200 | 89 (24) | 89 (100) | 0 (0) | 19 (12) | 26 (22) | 40 (43) |
| 200–499 | 161 (43) | 0 (0) | 161 (56) | 72 (47) | 54 (45) | 32 (35) |
| ≥500 | 127 (34) | 0 (0) | 127 (44) | 63 (41) | 39 (33) | 20 (22) |
| HIV RNA | ||||||
| ≤75 | 155 (42) | 19 (22) | 135 (48) | 155 (100) | 0 (0) | 0 (0) |
| 76–10 000 | 119 (33) | 26 (31) | 93 (33) | 0 (0) | 119 (100) | 0 (0) |
| >10 000 | 92 (25) | 40 (47) | 52 (19) | 0 (0) | 0 (0) | 92 (100) |
| Initiated ART | ||||||
| At baseline | 281 (81) | 65 (79) | 212 (82) | 130 (88) | 83 (80) | 62 (78) |
| In follow-up | 37 (11) | 12 (15) | 25 (10) | 13 (9) | 10 (10) | 9 (11) |
| Never | 27 (8) | 5 (6) | 21 (8) | 5 (3) | 11 (11) | 9 (11) |
| Variablea . | Total N = 383 N (%)b . | CD4 Count (Cells/mm3) . | HIV RNA Viral Load (Copies/mL) . | |||
|---|---|---|---|---|---|---|
| <200 N = 89 N (%)b . | ≥200 N = 288 N (%)b . | ≤75 N = 155 N (%)b . | 76–10 000 N = 119 N (%)b . | >10 000 N = 92 N (%)b . | ||
| Age >45 years | 212 (55) | 43 (48) | 166 (58) | 107 (69) | 62 (52) | 34 (37) |
| Male | 276 (72) | 66 (74) | 205 (71) | 118 (76) | 78 (66) | 66 (72) |
| Race | ||||||
| Black non-Hispanic | 171 (45) | 36 (40) | 132 (46) | 76 (49) | 48 (40) | 38 (41) |
| White non-Hispanic | 104 (27) | 24 (27) | 78 (27) | 38 (25) | 38 (32) | 25 (27) |
| Hispanic | 100 (26) | 28 (31) | 71 (25) | 37 (24) | 32 (27) | 26 (28) |
| Other | 8 (2) | 1 (1) | 7 (2) | 4 (3) | 1 (1) | 3 (3) |
| History of diabetes | 41 (11) | 9 (10) | 31 (11) | 24 (15) | 8 (7) | 7 (8) |
| Markers of HBV | 272 (78) | 68 (83) | 200 (76) | 111 (77) | 81 (76) | 71 (80) |
| FIB-4 | ||||||
| <1.45 (mild fibrosis) | 151 (41) | 32 (38) | 115 (41) | 64 (42) | 46 (39) | 36 (40) |
| 1.45–3.25 (moderate) | 147 (40) | 29 (34) | 117 (42) | 61 (40) | 48 (41) | 34 (38) |
| >3.25 (advanced) | 72 (19) | 24 (28) | 48 (17) | 29 (19) | 24 (20) | 19 (21) |
| HCV genotype 1 | 176 (80) | 41 (85) | 133 (79) | 74 (77) | 59 (83) | 39 (80) |
| HCV viral load ≥106 IU/mL | 106 (47) | 31 (58) | 74 (44) | 39 (44) | 36 (51) | 28 (47) |
| HCV treatment | 27 (7) | 4 (5) | 23 (8) | 13 (9) | 9 (8) | 5 (6) |
| Duration of IDU >25 years | 154 (48) | 40 (51) | 113 (47) | 67 (51) | 52 (53) | 30 (38) |
| Current IDU | 103 (27) | 30 (34) | 71 (25) | 30 (20) | 36 (31) | 30 (33) |
| AUDIT | ||||||
| <8 | 102 (56) | 24 (51) | 76 (58) | 40 (63) | 34 (57) | 24 (46) |
| 8–19 (hazardous) | 54 (30) | 14 (30) | 37 (28) | 13 (21) | 18 (30) | 20 (38) |
| ≥20 (dependence) | 27 (15) | 9 (19) | 18 (14) | 10 (16) | 8 (13) | 8 (15) |
| Nadir CD4 | ||||||
| <50 | 61 (16) | 46 (52) | 15 (5) | 22 (14) | 19 (16) | 18 (20) |
| 50–199 | 114 (30) | 42 (48) | 71 (25) | 48 (31) | 31 (26) | 32 (35) |
| ≥200 | 203 (54) | 0 (0) | 202 (70) | 85 (55) | 69 (58) | 41 (45) |
| CD4 | ||||||
| <200 | 89 (24) | 89 (100) | 0 (0) | 19 (12) | 26 (22) | 40 (43) |
| 200–499 | 161 (43) | 0 (0) | 161 (56) | 72 (47) | 54 (45) | 32 (35) |
| ≥500 | 127 (34) | 0 (0) | 127 (44) | 63 (41) | 39 (33) | 20 (22) |
| HIV RNA | ||||||
| ≤75 | 155 (42) | 19 (22) | 135 (48) | 155 (100) | 0 (0) | 0 (0) |
| 76–10 000 | 119 (33) | 26 (31) | 93 (33) | 0 (0) | 119 (100) | 0 (0) |
| >10 000 | 92 (25) | 40 (47) | 52 (19) | 0 (0) | 0 (0) | 92 (100) |
| Initiated ART | ||||||
| At baseline | 281 (81) | 65 (79) | 212 (82) | 130 (88) | 83 (80) | 62 (78) |
| In follow-up | 37 (11) | 12 (15) | 25 (10) | 13 (9) | 10 (10) | 9 (11) |
| Never | 27 (8) | 5 (6) | 21 (8) | 5 (3) | 11 (11) | 9 (11) |
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders identification test; FIB-4, fibrosis-4; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injecting drug use.
a Missing observations for each variable (N, %): age, 0 (0); sex, 0 (0); race, 0 (0); diabetes, 0 (0); HBV, 33 (9); FIB-4, 13 (3); HCV genotype, 162 (42); HCV viral load, 157 (41); HCV treatment, 19 (5); years of IDU, 60 (16); current IDU, 3 (1); alcohol, 200 (52); nadir CD4, 5 (1); CD4, 6 (2); HIV viral load, 17 (4); ART initiation, 38 (10).
b Percentages are among the nonmissing.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
